The historical rank and industry rank for Adaptive Biotechnologies's FCF Margin % or its related term are showing as below:
FRA:1HM'
s FCF Margin % Range Over the Past 10 Years
Min: -171.26 Med: -97.18 Max: 228.28
Current: -10.05
During the past 9 years, the highest FCF Margin % of Adaptive Biotechnologies was 228.28%. The lowest was -171.26%. And the median was -97.18%.
FRA:1HM's FCF Margin % is ranked worse than 61.27% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs FRA:1HM: -10.05
Adaptive Biotechnologies FCF Margin % Related Terms
Adaptive Biotechnologies FCF Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1HM vs GRAL, WGS, NEO: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Adaptive Biotechnologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptive Biotechnologies FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Adaptive Biotechnologies's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies (FRA:1HM) has a FCF Margin % of -14.58% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Adaptive Biotechnologies and its competitors. According to the industry distribution chart, Adaptive Biotechnologies ranks #125 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 61.3%.
Is Adaptive Biotechnologies' FCF Margin % too high?
Adaptive Biotechnologies' current FCF Margin % is -14.58%. Based on the distribution chart, Adaptive Biotechnologies ranks #125 out of 204 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Adaptive Biotechnologies has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' FCF Margin % compare to GRAL and WGS?
According to the Medical Diagnostics & Research industry distribution chart, Adaptive Biotechnologies ranks #125 out of 204 companies for FCF Margin %. This places Adaptive Biotechnologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current FCF Margin % is -14.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (FRA:1HM) is currently considered Significantly Overvalued. The stock's GF Value™ is €8.07, compared to a current price of €15.50 — trading 92.1% above its estimated fair value. The current FCF Margin % is -14.58%. Adaptive Biotechnologies' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Adaptive Biotechnologies (FRA:1HM), the current FCF Margin % is -14.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adaptive Biotechnologies (FRA:1HM) Overvalued in 2026?
Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued.
The current stock price of €15.50 is trading 92.1% above its estimated GF Value™ of €8.07.
GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.
Key valuation signals for FRA:1HM:
FCF Margin %: -14.58%
GF Value™: €8.07 vs. price of €15.50 (92.1% above fair value)
No single metric tells the full story. See the FRA:1HM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
73GF Score
Get the complete analysis for FRA:1HM
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1HM has been successfully added to your 
